EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma Journal Article
| Authors: | Kempf, W.; Pfaltz, K.; Vermeer, M. H.; Cozzio, A.; Ortiz-Romero, P. L.; Bagot, M.; Olsen, E.; Kim, Y. H.; Dummer, R.; Pimpinelli, N.; Whittaker, S.; Hodak, E.; Cerroni, L.; Berti, E.; Horwitz, S.; Prince, H. M.; Guitart, J.; Estrach, T.; Sanches, J. A.; Duvic, M.; Ranki, A.; Dreno, B.; Ostheeren-Michaelis, S.; Knobler, R.; Wood, G.; Willemze, R. |
| Article Title: | EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma |
| Abstract: | Primary cutaneous CD30+ lymphoproliferative disorders (CD30 + LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30+ LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30+ LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30+ PDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30+ LPDs. © 2011 by The American Society of Hematology. |
| Keywords: | cancer chemotherapy; treatment response; cancer surgery; excision; case-control studies; prednisone; thalidomide; cancer recurrence; doxorubicin; monotherapy; multimodality cancer therapy; united states; conference paper; alpha interferon; gemcitabine; cancer radiotherapy; methotrexate; cancer staging; outcome assessment; positron emission tomography; recurrence risk; follow up; diagnostic procedure; low drug dose; computer assisted tomography; cohort studies; imiquimod; etoposide; aciclovir; cyclophosphamide; steroid; vincristine; stem cell transplantation; information retrieval; cancer research; cancer therapy; histology; carmustine; chlormethine; gamma interferon; societies, medical; bone marrow biopsy; radiation dose fractionation; laboratory test; practice guidelines as topic; tumor cell; medical society; cancer relapse; thorax radiography; large cell lymphoma; physical examination; isotretinoin; tacrolimus; bone marrow transplantation; penicillin derivative; photodynamic therapy; photochemotherapy; cd30 ligand; radiation dermatitis; abdominal radiography; erythromycin; puva; european union; laser thermotherapy; sgn 30; bexarotene; psoralen; tetracycline derivative; lymphomatoid papulosis; brentuximab vedotin; miltefosine; sulfone derivative; european organization for research and treatment of cancer; excimer laser; international society for cutaneous lymphoma; united states cutaneous lymphoma consortium; viscum album; antigens, cd30; lymphoma, primary cutaneous anaplastic large cell |
| Journal Title: | Blood |
| Volume: | 118 |
| Issue: | 15 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2011-10-13 |
| Start Page: | 4024 |
| End Page: | 4035 |
| Language: | English |
| DOI: | 10.1182/blood-2011-05-351346 |
| PROVIDER: | scopus |
| PUBMED: | 21841159 |
| PMCID: | PMC3204726 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 November 2011" - "CODEN: BLOOA" - "Source: Scopus" |
